Reflecting on data presented at ASH 2025, Dr Kami Maddocks notes that several findings may change practice, including approval of epcoritamab combined with rituximab and lenalidomide (R2) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results